Advocacy intelligence hub — real-time data for patient organizations
treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC)
Ipsen
Treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use: BYLVAY may not be effective in PFIC type 2 patients with ABCB11 variants resulting in nonfunctional or complete absence of bile salt export pump protein (BSEP-3)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Bylvay
Ipsen Biopharmaceuticals, Inc.
Bylvay
(ODEVIXIBAT)Orphan drugIpsen Biopharmaceuticals, Inc.
Ileal Bile Acid Transporter Inhibitor [EPC]
12.1 Mechanism of Action Odevixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids (...
Browse all Progressive familial intrahepatic cholestasis news →
Giovanni Vitale, MD, LLP
IRCCS Azienda Ospedaliero-Universitaria di Bologna
📍 DEARBORN, MI
Bikrant B Lal, MD, DM
Institute of Liver and Biliary Sciences, New Delhi
View all Progressive familial intrahepatic cholestasis specialists →